-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nizubaglustat in Tay-Sachs Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nizubaglustat in Tay-Sachs Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nizubaglustat in Tay-Sachs Disease Drug Details: AZ-3102 (nizubaglustat) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nizubaglustat in Sandhoff Disease (Jatzkewitz-Pilz Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nizubaglustat in Sandhoff Disease (Jatzkewitz-Pilz Syndrome) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nizubaglustat in Sandhoff Disease (Jatzkewitz-Pilz Syndrome) Drug Details: AZ-3102 (nizubaglustat)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nizubaglustat in Niemann-Pick Disease Type C
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nizubaglustat in Niemann-Pick Disease Type C report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nizubaglustat in Niemann-Pick Disease Type C Drug Details: AZ-3102...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nizubaglustat in GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nizubaglustat in GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency) Drug Details: AZ-3102 (nizubaglustat) is under development...
-
Product Insights
Tay-Sachs Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Tay-Sachs Disease - Drugs In Development, 2023’, provides an overview of the Tay-Sachs Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Tay-Sachs Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Inherited Neurodegenerative Diseases – Drugs In Development, 2023
Global Markets Direct’s, ‘Inherited Neurodegenerative Diseases - Drugs In Development, 2023’, provides an overview of the Inherited Neurodegenerative Diseases pipeline landscape. The report provides comprehensive information on the therapeutics under development for Inherited Neurodegenerative Diseases, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...